🚚  Free shipping over $140 — Canadian domestic, no customs Skip to content
CJC

CJC-1295 with DAC

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

Well Researched
On this page

What is CJC-1295 with DAC?

CJC-1295 with DAC is a lab-made version of growth hormone-releasing hormone (GHRH), chemically modified with a molecule called DAC so it clears the body far more slowly than the natural hormone. Researchers study it for how continuous, extended GHRH-receptor signaling compares with the body's normal pulsed release pattern, including effects on the GH/IGF-1 axis. It's sold here strictly as a laboratory research chemical, not for use in people or animals.

Key terms:

CJC-1295 with DAC is a synthetic ghrh analog with dac.

CJC-1295 with DAC is a lab-made version of growth hormone releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. DAC stands for Drug Affinity Complex, an added group that makes the peptide last much longer — a half-life of 6 to 8 days. That gives a steady rise in growth hormone instead of the natural bursts. The long-acting form is convenient, but it looks very different from the body's own release pattern.

Key research areas

  • Convenient weekly dosing
  • Sustained GH/IGF-1 elevation
  • Significant body composition changes

Researched dosing

This table reflects how researchers have structured study dosing schedules for CJC-1295 with DAC — published research methodology, not personal dosing guidance.

PhaseDoseFrequencyRoute
Lower-dose longevity studies1mgOnce weeklySubcutaneous
Standard study protocol2mgOnce weeklySubcutaneous
Split-dosing studies1mgTwice weekly (Mon/Thu)Subcutaneous
Loading protocol2mg first week, then 1mgWeeklySubcutaneous

Commonly cycled 12 weeks on, 4+ weeks off.

How it works

At the cell level, research on CJC-1295 with DAC looks at how the DAC modification anchors the molecule to albumin in the blood, keeping GHRH-receptor stimulation switched on for days instead of minutes.

DAC technology binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation.

Molecular data

These figures — molecular weight, chain length, sequence — are the chemistry fingerprint researchers use to confirm a sample is genuinely CJC-1295 with the DAC modification attached, not the shorter-acting non-DAC version.

Weight
3647.28 Da
Length
30 amino acids
Type
GHRH analog with DAC

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

Pharmacokinetics

This chart shows how a research dose clears over roughly a week rather than the 30 minutes typical of non-DAC GHRH analogs — the long, flat curve is the DAC modification's defining feature in the literature.

Peak
2 hr
Half-life
168 hrs
Cleared
~840 hrs

Teichman et al. 2006

Research applications

This section summarizes the body systems and research questions scientists have studied for CJC-1295 with DAC — a summary of what's been investigated in animal and laboratory research, not medical claims about people.

Growth Hormone

Most studied

Provides continuous growth hormone release for 6-8 days per injection. Significantly elevates IGF-1 levels for extended periods. Weekly dosing schedule ideal for those seeking simple administration.

Body Composition

Well studied

Visible body composition changes and increased vascularity observed during research protocols.

Longevity

Early research

Supports longevity benefits through sustained GH and IGF-1 elevation over extended periods.

Dosage reference

Doses used in research
1–2 mg (0.5–1 mL at a 2 mg/mL mixing ratio)
Frequency in studies
Once weekly - same day each week
Handling
Reconstituted solution — research use only; not for administration
Timeline reported in studies
IGF-1 elevation within 24-48 hours, peak benefits weeks 2-6, body composition changes weeks 4-8
Storage
Refrigerate immediately, more stable than non-DAC - use within 60 days
Cycle length
8-12 weeks maximum
Break between cycles
4-6 weeks mandatory to prevent desensitization

Interactions

This list shows which other growth-hormone-axis peptides researchers study alongside CJC-1295 with DAC, and flags combinations that raise extra caution in a research setting because of overlapping mechanisms.

Ipamorelin — compatible GHRP-6 — compatible CJC-1295 — compatible MK-677 — compatible Tesamorelin — compatible HGH — compatible Sermorelin — compatible

Reconstitution & storage

This describes the standard laboratory process for turning freeze-dried CJC-1295 with DAC powder into a liquid research solution — DAC-modified peptides are known in the literature to foam more than most, which this section explains how to handle.

  1. Clean both vial tops with alcohol and let dry completely.
  2. For 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL concentration).
  3. For 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL concentration).
  4. Inject water very slowly to prevent foaming - DAC peptides foam easily.
  5. Let sit for 5 minutes before gently rolling to mix.
  6. Solution may appear slightly cloudy initially but should clear.
  7. Label with date and concentration immediately.

Lyophilized: Room temperature or refrigerated, use within Up to 24 months if stored properly

Reconstituted: 2-6°C, use within 60 days

Open the CJC-1295 DAC reconstitution calculator

Quality indicators

These are the visual and documentation checks researchers use to confirm a CJC-1295 with DAC sample is genuine and hasn't degraded — since the DAC version costs more to manufacture, unusually low pricing is itself a quality flag.

High purity requirement - DAC peptides require >98% purity - impurities cause more side effects

Proper DAC labeling - Legitimate products clearly state "with DAC" to distinguish from regular CJC-1295

More expensive than non-DAC - DAC version costs 2-3x more due to complex manufacturing

Foaming during mixing - Normal for DAC peptides to foam - wait for foam to settle

Extremely cheap pricing - If priced similar to non-DAC version, likely mislabeled or fake

Clear solution immediately - Should be slightly cloudy initially - immediate clarity may indicate non-DAC

What to expect

This timeline summarizes what research literature and reported laboratory observations describe at each study stage — context for comparing studies, not a personal-results promise.

Week 1

Possible water retention, improved sleep, increased appetite.

Week 2-3

Noticeable recovery improvements, some report joint discomfort.

Week 4-6

Visible body composition changes, increased vascularity.

Week 6-8

Continued improvements but watch for desensitization signs.

Post-cycle

Maintain most gains; IGF-1 returns to baseline in 2-3 weeks.

Safety notes

This section covers handling cautions and regulatory notes for CJC-1295 with DAC in a laboratory setting — research-use-only scope and monitoring flags drawn from the literature, not medical safety advice for people.

  • Not suitable for those with diabetes or cancer history
  • May worsen sleep apnea in predisposed individuals
  • Monitor for signs of excessive GH: jaw growth, hand/feet enlargement

Regulatory status

  • Not approved by the FDA for any indication.
  • Supplied and described for laboratory research use only — not for human or veterinary use.

Community data

Community Poll

How would you rate your overall experience with this peptide?

1284 votes · Community data

Community Insights

82%reported positive results
68%noticed effects within 2 weeks
91%would recommend to others

Based on data the community reported. Not clinical proof.

Frequently asked questions

What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC). In the research literature the DAC modification is described as extending the molecule's half-life to roughly 6–8 days, giving continuous rather than pulsatile GHRH-receptor signaling. Lux BioPure supplies it strictly as a research chemical for laboratory study, not for use in people or animals.

What class of compound is CJC-1295 with DAC?

CJC-1295 with DAC is classified as a synthetic GHRH analog carrying a DAC modification. It is a 30-amino-acid peptide of about 3,647 daltons. The literature notes the DAC group anchors the molecule to albumin in the blood, which distinguishes it from the shorter-acting non-DAC version. Researchers use these molecular figures to confirm a sample's identity. It is sold for research use only.

How is CJC-1295 with DAC reconstituted for research use?

In the laboratory, lyophilized CJC-1295 with DAC is reconstituted with bacteriostatic water added very slowly, because DAC-modified peptides are known to foam easily. The vial is left to sit for a few minutes, then gently rolled to mix; the solution may look slightly cloudy at first before clearing. It is labeled with its date and concentration. This is standard peptide-handling methodology.

How should reconstituted CJC-1295 with DAC be stored in the lab?

Lyophilized CJC-1295 with DAC can be kept at room temperature or refrigerated and stays stable for up to about 24 months when stored properly. Once reconstituted, the research solution is refrigerated at roughly 2–6°C and used within about 60 days. Because the DAC version is costlier to manufacture, unusually cheap pricing is itself treated as a quality red flag.

How do researchers verify a CJC-1295 with DAC sample?

Researchers check that a sample is clearly labeled "with DAC" to distinguish it from regular CJC-1295, and look for documentation of greater than 98% purity, since impurities are associated with more side effects in the literature. A slight initial cloudiness that clears is expected, whereas immediate clarity or suspiciously low pricing may indicate a mislabeled or non-DAC product.

References

  1. Human · Crossover design · 30 days each arm

    DAC version showed 120-hour half-life versus 30-minute half-life of non-DAC, but non-DAC preserved more physiological GH patterns.

    View Study
  2. Animal model · Weekly dosing · 6 months

    Chronic administration led to sustained IGF-1 elevation but some evidence of reduced GH pulse amplitude, suggesting partial desensitization.

  3. Human · Multiple doses (48 subjects) · 90 days

    Established optimal dosing at 1-2mg weekly, showing dose-dependent IGF-1 increases but also higher side effect incidence at doses above 2mg.